Brexit Briefing Webinar - July
Thursday 16 July, 11:00 - 12:00 BST
This webinar is part of a series of BIA Brexit Briefings that provide updates for our UK and International audiences answering 'What does Brexit mean for Biotechnology in the UK and beyond?
Following the outcome of the UK’s referendum on membership of the European Union, the BIA has worked closely with members and stakeholders to identify the threats and opportunities for biotech post-Brexit and to represent the sector.
Our BIA Brexit Briefing webinars provide a monthly update on Government policy, progress of working groups, and how these potentially affect companies in life sciences. Visit our dedicated microsite www.biabrexit.org to view all the information and guidance for the sector.
Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.
Emma Du Four B.Sc. (Hons), MBA, FTOPRA
Emma Du Four is Head of International Regulatory Policy at AbbVie. She leads a team providing strategic guidance on key regulatory policy issues and external advocacy in support of access for patients to innovative medicines.
Emma has an honours degree in Biochemistry, a Masters degree in Business Administration and is a Fellow of the organisation for professionals in regulatory affairs. She partners with an extensive external network of industry, government, academic and healthcare system partners and has a broad range of experience across all aspects of innovative medicines development. Specific areas of expertise include regulatory policy & strategy development, clinical trials, biotechnology, real world evidence, pharmacovigilance and paediatric drug development.
Emma regularly represents AbbVie and industry more broadly on scientific and technical issues. She is Chair of the BioIndustry Association Regulatory Affairs Advisory Committee and Vice-Chair of the European Regulatory Expert Group. She has been influential in shaping the current global regulatory environment.
Free for members and non-members
By registering to this event you accept our Terms & Conditions